Overview

The Gene Technology Act 2000, enacted by the Australian Parliament, is a piece of legislation designed to regulate the handling, storage, use, and disposal of genetically modified organisms, including genetically modified organisms used in clinical trials. This Act was introduced to address the need for stringent oversight and regulation of gene technology activities to protect human health and the environment. The policy objective of the Act is to ensure that gene technology activities are conducted in a manner that safeguards public health and the environment while fostering innovation and research. The Gene Technology Regulator, under this Act, is currently assessing an application from Ferring Pharmaceuticals Pty Ltd to conduct a clinical trial using a genetically modified adenovirus for bladder cancer treatment. The Regulator has prepared a Risk Assessment and Risk Management Plan (RARMP) to evaluate the potential risks and manage them appropriately, and is inviting written submissions from the public to inform its decision-making process.

Scope and Application

The proposed clinical trial of a genetically modified human adenovirus for bladder cancer treatment by Ferring Pharmaceuticals Pty Ltd is subject to the oversight of the Gene Technology Regulator, which is responsible for assessing the application under the Gene Technology Act 2000. This Act applies to entities and individuals involved in activities that involve gene technology, including the proposed clinical trial. The scope of the legislation is national, with the Regulator operating under the authority of the Commonwealth of Australia, but it also aligns with international obligations and guidelines concerning the safety and ethical conduct of clinical trials involving genetically modified organisms. The proposed trial will be subject to a Risk Assessment and Risk Management Plan, which is designed to safeguard human health and the environment. The consultation period allows for public submissions to be made, which are critical in informing the Regulator's decision on whether to issue the necessary licence for the trial. This process is inclusive and transparent, inviting contributions from relevant stakeholders, including medical professionals, ethicists, and the general public, to ensure comprehensive consideration of the potential risks and benefits of the proposed treatment. Submissions must reference DIR 223 and be submitted by the specified deadline to ensure they are considered in the decision-making process.

Key Provisions

The main sections of this legislation pertain to the assessment and approval process for a clinical trial application submitted by Ferring Pharmaceuticals Pty Ltd (Section 1). The application is for a clinical trial of a genetically modified human adenovirus intended for the treatment of bladder cancer. The trial is to be conducted under limited and controlled conditions at clinical trial sites and hospitals across Australia, with up to 13 participants over a period of five years. The Gene Technology Regulator has prepared a Risk Assessment and Risk Management Plan (RARMP) to evaluate the potential risks to human health and safety and the environment associated with this trial. In terms of obligations, the Act imposes specific requirements on Ferring Pharmaceuticals Pty Ltd as the applicant. These include the submission of a detailed application that outlines the proposed clinical trial's methodology, participant selection criteria, and safety measures. Ferring must also provide comprehensive data to support the safety and efficacy of the genetically modified adenovirus, as well as a risk management plan that addresses potential environmental and health impacts. The Regulator is tasked with reviewing the application, the RARMP, and any public submissions to determine whether the proposed trial meets the necessary safety and ethical standards. Breaches of the provisions under this legislation can lead to various consequences. If the clinical trial is conducted without the required approval or in a manner that contravenes the approved conditions, it could result in significant civil and criminal penalties. The maximum penalties for non-compliance can include substantial fines and potential imprisonment for responsible individuals. These penalties underscore the importance of adhering to the Act’s requirements to protect human health and the environment. Furthermore, failure to comply with public consultation and submission requirements may also result in legal repercussions, highlighting the necessity of transparent and inclusive processes in the decision-making framework.